The company said it selected two drug candidates for clinical testing as treatments for Covid-19. The lead candidate is able to bind to a region common to the SARS-CoV-2 and 2002-2003 SARS viruses, indicating the viruses may be unable to mutate and become resistant to the drug.

LEAVE A REPLY

Please enter your comment!
Please enter your name here